Medtronic Reaffirms 2026 Outlook As Heart and Diabetes Units Drive Growth
Medtronic Plc (NYSE:MDT) on Tuesday reported third-quarter 2026 results, with sales hitting $9.02 billion, surpassing the consensus estimate of $8.91 billion. This marks an 8.7% increase year-over-year, with organic growth of 6%.
Adjusted earnings of $1.36 per share also beat expectations of $1.33.
Segment Performance
Cardiovascular Portfolio revenue of $3.457 billion, an increase of 13.8% as reported and 10.6% organic, with high-teens increase in Cardiac Rhythm & Heart Failure, low-single digit increase in Structural Heart & Aortic, and mid-single digit increase in Coronary & Peripheral Vascular, all on an organic basis.
Neuroscience Portfolio revenue of $2.558 billion, an increase of 4.1% reported and 2.5% organic, with a mid-single digit increase in Neuromodulation, a mid-single digit increase in Cranial & Spinal Technologies, and flat results in Specialty Therapies, all on an organic basis
Medical Surgical Portfolio revenue of $2.173 billion, an increase of 4.9% as reported and 2.7% organic, with a low-single digit increase in Surgical & Endoscopy, and a high-single digit increase in Acute Care & Monitoring, all on an organic basis
Diabetes business revenue of $796 million, an increase of 14.8% as reported and 8.3% organic.
“Q3 marks another strong quarter, delivering 6% organic revenue growth, ahead of guidance, demonstrating the strength of our portfolio,” said Geoff Martha, Medtronic chairman and CEO.
Outlook
Medtronic reiterates its fiscal 2026 organic revenue growth of approximately 5.5% and adjusted earnings per share guidance of $5.62 to $5.66.
The guidance includes a potential impact from tariffs of approximately $185 million, unchanged from the prior guidance.
Excluding the potential impact from tariffs, the guidance represents fiscal 2026 adjusted EPS growth of approximately 4.5%.
“This quarter, we again delivered accelerated growth while investing decisively in our future,” said Thierry Piéton, Medtronic CFO.
“We continued to invest in R&D to strengthen our innovation pipeline, funded significant growth opportunities while driving G&A leverage, and we executed on our M&A and venture strategy with two key transactions in the quarter. Bottom line, we are executing on our roadmap and positioning the business for sustainable growth.”
In February, Medtronic announced to exercise its option to acquire CathWorks, a privately held medical device company based in Israel.
The acquisition is valued at up to $585 million with potential undisclosed earn-out payments post-acquisition.
MDT Price Action: Medtronic shares were down 2.84% at $96.66 at the time of publication on Tuesday, according to Benzinga Pro data.
Image via Shutterstock
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Jensen Huang's sudden resignation shrouded in suspicion: Did the White House secretly intervene? Is a return possible in the future?
Only a few days separated Jensen Huang’s strong support from the board last Sunday and his late-night resignation on Wednesday. Multiple reports of the Wednesday night Nvidia board meeting were co-authored by Washington-based journalists—who do not typically cover Nvidia—fueling rumors of "White House pressure and information leaks." Huang’s unique value lies in leveraging his personal reputation to secure the supply chain and drive the implementation of technological roadmaps, making him difficult to replace. Some analysts note that, drawing on examples such as Steve Jobs’ return to Apple, it is possible that Huang may come back in the future.
Gold recovers from YTD low, retakes $3,900; Fed hike bets and bullish USD to cap gains
Cerebras (CBRS.US) Cloud Business Soars, Masking Hardware Decline; OpenAI Supports Half of Cloud Revenue
Cerebras achieved record Q3 revenue, but hardware income dropped by nearly 30%, while cloud business accounted for two-thirds of total revenue. OpenAI contributed $72.4 million. The company raised its full-year guidance and expects Q4 to be close to breakeven.
Crypto prices
More
